Literature DB >> 8651171

Chronic hepatitis C in patients with sickle cell disease.

M F Hasan1, F Marsh, G Posner, R Bellevue, H Dosik, R Suatengco, N Ramani.   

Abstract

OBJECTIVE: To determine the prevalence of hepatitis C virus (HCV) antibody in patients with sickle cell disease and to analyze the nature of chronic liver disease in these patients.
METHODS: A total of 99 patients attending a comprehensive sickle cell and thalassemia program at the Interfaith Medical Center, Brooklyn, NY, participated in the study. Eighty-five patients had sickle cell anemia (ss), eight had sickle C disease (sc), and six had sickle B thalassemia. History of blood transfusion, i.v. drug use, homosexuality, and alcohol abuse was obtained with a questionnaire and chart review. All patients were screened for HCV antibody by a first generation enzyme-linked immunosorbent assay. All positive results were confirmed with radioimmunoblot assay II (RIBA II). Patients were also checked for the presence of hepatitis B surface antigen. ALT levels were measured, and percutaneous liver biopsies were performed in patients positive for HCV antibody and greater than 1.5 times the normal ALT levels.
RESULTS: Antibody to HCV was detected in 10/99 patients (10.10%). Seven of 30 patients (23.33%) who received more than 10 U of packed red blood cells were positive for HCV antibody. Only 3/38 (7.9%) patients with less than 10 U of packed red blood cells in the past were positive for HCV antibody. None of the patients who never received blood transfusion were positive for HCV antibody (0/31 or 0%). A total of seven liver biopsies were performed in patients positive for HCV antibody. Two out of seven specimens (28.57%) showed significant liver damage. One revealed cirrhosis, and the other showed chronic active hepatitis. The remainder of liver biopsies (5/7; 71.42%) showed only mild portal inflammation.
CONCLUSIONS: The prevalence of HCV antibody is directly related to the number of blood transfusions in patients with sickle cell disease. Chronic HCV infection could be a major cause of cirrhosis of the liver in these patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651171

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

Review 1.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

2.  Hepatitis C virus in sickle cell disease.

Authors:  Mohamed Hassan; Syed Hasan; Samuel Giday; Laila Alamgir; Alpha Banks; Winston Frederick; Duane Smoot; Oswaldo Castro
Journal:  J Natl Med Assoc       Date:  2003-10       Impact factor: 1.798

Review 3.  HCV in sickle cell disease.

Authors:  Mohamed Hassan; Syed Hasan; Oswaldo Castro; Samuel Giday; Alpha Banks; Duane Smoot
Journal:  J Natl Med Assoc       Date:  2003-09       Impact factor: 1.798

4.  Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia.

Authors:  Adnan Agha; Rafaat Chakik; Mamdouh M Abdulhadi Ali; Dib Alsaudi; Giorgio Sammito; Edoardo Giovanni Giannini
Journal:  Ann Saudi Med       Date:  2013 Nov-Dec       Impact factor: 1.526

Review 5.  Sickle Hepatopathy.

Authors:  Dibya L Praharaj; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2020-08-09

6.  Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia.

Authors:  Nikolaos Papadopoulos; Melanie Deutsch; Athanasios Georgalas; Helias Poulakidas; Lazaros Karnesis
Journal:  Case Rep Hematol       Date:  2016-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.